AC Immune SA - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AC Immune SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AC Immune SA - Product Pipeline Review - 2014', provides an overview of the AC Immune SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AC Immune SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AC Immune SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AC Immune SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AC Immune SA's pipeline products

Reasons to buy

- Evaluate AC Immune SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AC Immune SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AC Immune SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AC Immune SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AC Immune SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AC Immune SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
AC Immune SA Snapshot 5
AC Immune SA Overview 5
Key Information 5
Key Facts 5
AC Immune SA - Research and Development Overview 6
Key Therapeutic Areas 6
AC Immune SA - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
AC Immune SA - Pipeline Products Glance 14
AC Immune SA - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
AC Immune SA - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
AC Immune SA - Drug Profiles 17
ACI-24 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ACI-35 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ACI-260 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ACI-812 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule to Inhibit Tau Protein for Alzheimer's Disease 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AC Immune SA - Pipeline Analysis 23
AC Immune SA - Pipeline Products by Target 23
AC Immune SA - Pipeline Products by Molecule Type 24
AC Immune SA - Pipeline Products by Mechanism of Action 25
AC Immune SA - Recent Pipeline Updates 26
AC Immune SA - Dormant Projects 27
AC Immune SA - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
pirenzepine 28
AC Immune SA - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31

List of Tables
AC Immune SA, Key Information 5
AC Immune SA, Key Facts 5
AC Immune SA - Pipeline by Indication, 2014 7
AC Immune SA - Pipeline by Stage of Development, 2014 8
AC Immune SA - Monotherapy Products in Pipeline, 2014 9
AC Immune SA - Partnered Products in Pipeline, 2014 10
AC Immune SA - Partnered Products/ Combination Treatment Modalities, 2014 11
AC Immune SA - Out-Licensed Products in Pipeline, 2014 12
AC Immune SA - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
AC Immune SA - Phase I, 2014 14
AC Immune SA - Preclinical, 2014 15
AC Immune SA - Discovery, 2014 16
AC Immune SA - Pipeline by Target, 2014 23
AC Immune SA - Pipeline by Molecule Type, 2014 24
AC Immune SA - Pipeline Products by Mechanism of Action, 2014 25
AC Immune SA - Recent Pipeline Updates, 2014 26
AC Immune SA - Dormant Developmental Projects,2014 27
AC Immune SA - Discontinued Pipeline Products, 2014 28